NASDAQ: VIGLVigil Neuroscience Inc Stock
$2.58-0.19 (-6.86%)
Updated Apr 25, 2024
VIGL Price
$2.58
Fair Value Price
$0.99
Market Cap
$95.16M
52 Week Low
$2.53
52 Week High
$11.11
P/E
-1.21x
P/B
0.82x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$82.64M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$70M
Beta
0.94
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
VIGL Overview
Vigil Neuroscience Incorporated is a microglia-focused company that develops disease-modifying therapeutics for rare and common neurodegenerative diseases. Its lead product candidate is VGL101 is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company was incorporated in 2020 and is headquartered in Cambridge, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VIGL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VIGL ($2.58) is overvalued by 161.86% relative to our estimate of its Fair Value price of $0.99 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VIGL ($2.58) is not significantly undervalued (161.86%) relative to our estimate of its Fair Value price of $0.99 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VIGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VIGL due diligence checks available for Premium users.
Be the first to know about important VIGL news, forecast changes, insider trades & much more!
VIGL News
Valuation
VIGL fair value
Fair Value of VIGL stock based on Discounted Cash Flow (DCF)
Price
$2.58
Fair Value
$0.99
Overvalued by
161.86%
VIGL ($2.58) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VIGL ($2.58) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VIGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VIGL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.21x
Industry
15.41x
Market
40.97x
VIGL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.82x
Industry
5.8x
VIGL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VIGL's financial health
Profit margin
Revenue
$0.0
Net Income
-$22.2M
Profit Margin
0%
VIGL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$140.9M
Liabilities
$24.6M
Debt to equity
0.21
VIGL's short-term assets ($121.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VIGL's short-term assets ($121.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VIGL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.5M
Investing
$10.7M
Financing
$53.0k
VIGL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VIGL vs Biotech Stocks
Vigil Neuroscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.